approves
-
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically targeting…
Read More » -
Alzheimer’s & Dementia Care
U.S. FDA Approves Leqembi Iqlik Subcutaneous Autoinjector for Early Alzheimer’s Disease Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has announced the approval of Leqembi Iqlik (lecanemab-irmb), an innovative under-the-skin autoinjector formulation…
Read More » -
Alzheimer’s & Dementia Care
Health Canada Conditionally Approves Leqembi, Marking a Pivotal Shift in Alzheimer’s Treatment by Targeting Underlying Disease Cause
Health Canada has granted conditional approval for Leqembi (lecanemab), a groundbreaking therapy co-developed by Eisai and Biogen, for specific adults…
Read More »
